MDR-1 gene polymorphisms G2677T and C3435T in a case of Hodgkin's variant of Richter's syndrome

Penna,Giuseppa; Allegra,Alessandro; Alonci,Andrea; Aguennouz,Mohamed; Cannavò,Antonino; Russo,Sabina; Granata,Angela; Musolino,Caterina

doi:10.3892/ol.2011.243

MDR-1 gene polymorphisms G2677T and C3435T in a case of Hodgkin's variant of Richter's syndrome

Authors:
- Giuseppa Penna
- Alessandro Allegra
- Andrea Alonci
- Mohamed Aguennouz
- Antonino Cannavò
- Sabina Russo
- Angela Granata
- Caterina Musolino
View Affiliations

Affiliations: Division of Hematology, Policlinico G. Martino, University of Messina, 98100 Messina, Italy, Department of Neuroscience, Policlinico G. Martino, University of Messina, Messina, Italy
Published online on: January 20, 2011 https://doi.org/10.3892/ol.2011.243
Pages: 379-381

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Richter's syndrome is defined as the transformation of low-grade lymphoma to a more aggressive high-grade malignant form, usually diffuse large B-cell lymphoma. Hodgkin's lymphoma variant of Richter transformation is relatively rare, and only approximately 100 cases have been reported in the literature. This study examined a case of a 53-year-old woman who developed Hodgkin's lymphoma almost 5 years after the diagnosis of chronic lymphocytic leukemia (CLL). The major points of interest regarding CLL with Hodgkin's transformation were also considered, such as the potential role of MDR-1 gene polymorphisms. The patient was evaluated for two MDR-1 gene polymorphisms, G2677T polymorphism in exon 21 and silent C3435T polymorphism in exon 26, to ascertain whether polymorphisms affect the risk of Hodgkin's lymphoma variant of Richter transformation and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. According to the data obtained, the analysis of polymorphisms in the MDR1 gene exons 21 and 26 revealed that the T2677T and T3435T alleles are not a predisposing factor to Richter transformation, while the presence of the wild-type genotype may be associated with a more favorable response to therapy.

View Figures

View References

1	Tsimberidou AM, O’Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE and Keating MJ: Hodgkin transformation of chronic lymphocytic leukemia: the MD Anderson Cancer Center experience. Cancer. 107:1294–1302. 2006. View Article : Google Scholar
2	Almhanna K, Wongchawart N and Sweetenham J: Intracerebral Hodgkin’s lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and literature review. Cancer Invest. 27:215–220. 2009.
3	Prochorec-Sobieszek M, Majewski M, Sikorska A, Kos K, Huszcza S and Maryniak RK: Localized gastric diffuse large B-cell lymphoma and Hodgkin’s lymphoma as secondary neoplasms in two patients with chronic lymphocytic leukemia. Leuk Lymph. 47:2244–2246. 2006.
4	Roddie C, Cwynarski K, Craig C, Diss T and McNamara C: Hodgkin transformation of newly diagnosed small lymphocytic lymphoma in the gastrointestinal tract. Leuk Lymph. 48:1644–1646. 2007. View Article : Google Scholar : PubMed/NCBI
5	Adiga GU, Abebe L and Wiernik PH: Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin’s disease: case report and literature review. Am J Hematol. 72:267–273. 2003.PubMed/NCBI
6	Robertson LE, Pugh W, O’Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, McLaughlin P, Cabanillas F and Keating MJ: Richter’s syndrome: a report on 39 patients. J Clin Oncol. 11:1985–1989. 1993.
7	Brecher M and Banks PM: Hodgkin’s disease variant of Richter’s syndrome. Report of eight cases. Am J Clin Pathol. 93:333–339. 1990.
8	Kanzler H, Kuppers R, Helmes S, Wacker HH, Chott A, Hansmann ML and Rajewsky K: Hodgkin and Reed-Sternberg-like cells in B-CLL chronic lymphocytic leukemia represent the outgrowth of single germinal-center B-cell-derived clones: potential precursors of Hodgkin and Reed-Sternberg cells in Hodgkin’s disease. Blood. 95:1023–1031. 2000.PubMed/NCBI
9	Fong D, Kaiser A, Spizzo G, Gastl G and Tzankov A: A Hodgkin’s disease variant of Richter’s syndrome in chronic lymphocytic leukemia patients previously treated with fludarabine. Br J Haematol. 129:199–205. 2005.
10	Dujardin F, Lefrancq T, Bléchet C, Boni-Boka M, Sénecal D, Desmoulins I and Guyetant S: Syndrome de Richter de type pseudohodgkinien. A propos de deux cas et revue de la literature. Annales de Pathologie. 28:311–316. 2008. View Article : Google Scholar : PubMed/NCBI
11	Lazzarino M, Orlandi E, Baldanti F, Furione M, Pagnucco G, Astori C, Arcaini L, Viglio A, Paulli M, Gerna G and Bernasconi C: The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. Br J Haematol. 107:877–882. 1999. View Article : Google Scholar : PubMed/NCBI
12	Niscola P, Principe MI, Palombi M, et al: Hodgkin lymphoma in a mutated ZAP-70-negative B-cell chronic lymphocytic leukemia patient. Leuk Res. 32:362–365. 2008. View Article : Google Scholar : PubMed/NCBI
13	Cerny J, Wang S, Miron P, Hutchinson L and Brettler D: EBV-negative Hodgkin lymphoma in ZAP-70-positive B-cell lymphocytic leukemia patient. Ann Hematol. 88:495–497. 2009. View Article : Google Scholar : PubMed/NCBI
14	Pescaramona E, Pignoloni P, Mauro FR, Cerretti R, Anselmo AP, Mandelli F and Baroni CD: Hodgkin/Reed-Sternberg cells and Hodgkin’s disease in patients with B-cell chronic lymphocytic leukaemia: an immunohistological, molecular and clinical study of four cases suggesting a heterogeneous pathogenic background. Virchows Arch. 437:129–132. 2000.
15	Hamblin TJ, Davis Z, Gardiner A, Oscier DG and Stevenson FK: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 94:1848–1854. 1999.PubMed/NCBI
16	Landgreen O, Pfeiffer RM, Stewart L, Gridley G, Mellemkjaer L, Hemminki K, Goldin LR and Travis LB: Risk of second malignant neoplasms among lymphoma patients with a family history of cancer. Int J Cancer. 120:1099–1102. 2007. View Article : Google Scholar : PubMed/NCBI
17	World Health Organization. Monographs on the evaluation of carcinogenic risks to humans – overall evaluation of carcinogenety. IARC; Lyon: 1987
18	Maddocks-Christianson K, Slager SL, Zent CS, Reinalda M, Call TG, Habermann TM, Bowen DA, Hoyer JD, Schwager S, Jelinek DF, Kay NE and Shanafelt TD: Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol. 139:398–404. 2007. View Article : Google Scholar : PubMed/NCBI
19	Cheson BD, Vena DA, Barrett J and Freidlin B: Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 17:2454–2460. 1999.PubMed/NCBI
20	Alebouyeh M, Moussavi F, Haddad-Deylami H and Vossough P: Hodgkin lymphoma as second malignancy during continuing chemotherapy for childhood acute lymphoblastic leukemia. Klin Padiatr. 220:388–390. 2008. View Article : Google Scholar
21	Potocnik U, Ravnik-Glavac M and Glavac D: Functional MDR1 polymorphisms (G2677T and C3435T) and TCF4 mutations in colorectal tumors with high microsatellite instability. Cell Mol Biol Lett. 7:92–95. 2002.PubMed/NCBI
22	Golapud S and Gupta S: Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival. J Clin Immunol. 21:420–430. 2001. View Article : Google Scholar : PubMed/NCBI
23	Wulf G, Kluding H, Ho AD, Doerner M, Doehner H, Manegold C and Hunstein W: Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and northen blot analysis. Leuk Res. 18:475–484. 1994. View Article : Google Scholar : PubMed/NCBI
24	Marzolini C, Paulus E, Buclin T and Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 75:13–33. 2004. View Article : Google Scholar : PubMed/NCBI
25	Kim DH, Park JY, Sohn SK, Lee NY, Baek JH, Jeon SB, Kim JG, Suh JS, Do YR and Lee KB: Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in the novo acute myeloid leukemia. Int J Cancer. 118:2195–2201. 2005. View Article : Google Scholar : PubMed/NCBI
26	Jamroziak K, Balcerczak E, Smolewski P, Robey RW, Cebula B, Panczyk M, Kowalczyk M, Szmigielska-Kapłon A, Mirowski M, Bates SE and Robak T: MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep. 58:720–728. 2006.PubMed/NCBI
27	Goreva OB, Grishanova AY, Mukhin OV, Domnikova NP and Lyakhovich VV: Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms. Bull Exp Biol Med. 136:183–185. 2003. View Article : Google Scholar : PubMed/NCBI
28	Penna G, Allegra A, Alonci A, et al: MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis. Med Oncol. May 22–2010.(E-pub ahead of print).
29	Aydin S, Rossi D, Bergui L, D’Arena G, Ferrero E, Bonello L, Omedé P, Novero D, Morabito F, Carbone A, Gaidano G, Malavasi F and Deaglio S: CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood. 111:5646–5653. 2008. View Article : Google Scholar : PubMed/NCBI
30	Rossi D and Gaidano G: Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol. 27:1–10. 2009. View Article : Google Scholar : PubMed/NCBI